FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Arthur Frankel

Research Profile

Chemicals & Drugs

Anatomy

Disorders

Living Beings

Mouse

Physiology

Drug Resistance, Neoplasm

Co-author Network

Publications

TOP 3
Elias Kassab; Stephen H Leppla; Shihui Liu; Zahra Timsah; Manal Darwish; Arthur E Frankel; Ralph J Abi-Habib
Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity.
Hyun Pyo Kim; Arthur E Frankel; Donna E Hogge
A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia.
Daniel A Vallera; Seunguk Oh; Hua Chen; Yanqun Shu; Arthur E Frankel
Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Arthur Frankel (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Elias Kassab; Stephen H Leppla; Shihui Liu; Zahra Timsah; Manal Darwish; Arthur E Frankel; Ralph J Abi-Habib
Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity.
Translational oncology 2013;6(1):25-32.
2010: Hyun Pyo Kim; Arthur E Frankel; Donna E Hogge
A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia.
Leukemia research 2010;34(8):1035-42.
2010: Daniel A Vallera; Seunguk Oh; Hua Chen; Yanqun Shu; Arthur E Frankel
Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.
Molecular cancer therapeutics 2010;9(6):1872-83.
2010: Yunpeng Su; Shi-Yan Li; Sunil Ghosh; Janelle Ortiz; Donna E Hogge; Arthur E Frankel
Characterization of variant diphtheria toxin-interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials.
Biologicals : journal of the International Association of Biological Standardization 2010;38(1):144-9.
2009: Henrick Horita; Jacqueline Thorburn; Arthur E Frankel; Andrew Thorburn
EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins.
Journal of neuro-oncology 2009;95(2):175-84.
2009: Jacqueline Thorburn; Arthur E Frankel; Andrew Thorburn
Regulation of HMGB1 release by autophagy.
Autophagy 2009;5(2):247-9.
2008: Shu-Ru Kuo; Mark C Willingham; Sarah H Bour; Elissa A Andreas; Seong Kyu Park; Carney Jackson; Nicholas S Duesbery; Stephen H Leppla; Wei-Jen Tang; Arthur E Frankel
Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage.
Microbial pathogenesis 2008;44(6):467-72.
2008: Randall W Alfano; Stephen H Leppla; Shihui Liu; Thomas H Bugge; Nicholas S Duesbery; Arthur E Frankel
Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy.
Cell cycle (Georgetown, Tex.) 2008;7(6):745-9.
2008: Yan Ding; Elissa A Boguslawski; Bree D Berghuis; John J Young; Zhongfa Zhang; Kim Hardy; Kyle A Furge; Eric Kort; Arthur E Frankel; Rick V Hay; James Resau; Nicholas S Duesbery
Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma.
Molecular cancer therapeutics 2008;7(3):648-58.
2007: Philippe Depeille; John J Young; Elissa A Boguslawski; Bree Berghuis; Eric J Kort; James Resau; Arthur E Frankel; Nicholas S Duesbery
Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(19):5926-34.
2007: Ravibhushan Singh; Jeff Browning; Ralph J Abi-Habib; Kevin Wong; Simon A Williams; Rosemina Merchant; Samuel R Denmeade; Thomas J Buckley; Arthur E Frankel
Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity.
Anti-cancer drugs 2007;18(7):809-16.
2007: Yunpeng Su; Janelle Ortiz; Shihui Liu; Thomas H Bugge; Ravibhushan Singh; Stephen H Leppla; Arthur E Frankel
Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice.
Cancer research 2007;67(7):3329-36.
2006: Ralph J Abi-Habib; Ravibhushan Singh; Stephen H Leppla; John J Greene; Yan Ding; Bree Berghuis; Nicholas S Duesbery; Arthur E Frankel
Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(24):7437-43.
2006: Leman Yalcintepe; Arthur E Frankel; Donna E Hogge
Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice.
Blood 2006;108(10):3530-7.
2006: Ralph J Abi-Habib; Ravibhushan Singh; Shihui Liu; Thomas H Bugge; Stephen H Leppla; Arthur E Frankel
A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types.
Molecular cancer therapeutics 2006;5(10):2556-62.
2006: Philip D Hall; Debajyoti Sinha; Arthur E Frankel
Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: Implications for diphtheria fusion protein therapy.
Cancer immunology, immunotherapy : CII 2006;55(8):928-32.
2006: Arthur E Frankel; Asha Surendranathan; Jennifer H Black; Angela White; Kristen N Ganjoo; Larry D Cripe
Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.
Cancer 2006;106(10):2158-64.
2006: Donna E Hogge; Leman Yalcintepe; Siaw-Hui Wong; Brigitte Gerhard; Arthur E Frankel
Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(4):1284-91.
2006: Andrew Thorburn; Arthur E Frankel
Apoptosis and anthracycline cardiotoxicity.
Molecular cancer therapeutics 2006;5(2):197-9.
2005: Ralph J Abi-Habib; Jeffrey O Urieto; Shihui Liu; Stephen H Leppla; Nicholas S Duesbery; Arthur E Frankel
BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin.
Molecular cancer therapeutics 2005;4(9):1303-10.
2005: Kimberley A Cohen; Tie Fu Liu; J Mark Cline; Janice D Wagner; Philip D Hall; Arthur E Frankel
Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey.
Cancer immunology, immunotherapy : CII 2005;54(8):799-806.
2005: Tie Fu Liu; Philip D Hall; Kimberley A Cohen; Mark C Willingham; Jiaozhong Cai; Andrew Thorburn; Arthur E Frankel
Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):329-34.
2004: Marlena M Westcott; Ralph J Abi-Habib; Kimberley A Cohen; Mark C Willingham; Shihui Liu; Thomas H Bugge; Stephen H Leppla; Arthur E Frankel
Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells.
Molecular cancer therapeutics 2004;3(12):1681-9.
2004: Donna E Hogge; Michaela Feuring-Buske; Brigitte Gerhard; Arthur E Frankel
The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia.
Leukemia research 2004;28(11):1221-6.
2004: Ralph J Abi-Habib; Shihui Liu; Thomas H Bugge; Stephen H Leppla; Arthur E Frankel
A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts.
Blood 2004;104(7):2143-8.
2004: Kimberley A Cohen; Tie Fu Liu; J Mark Cline; Janice D Wagner; Philip D Hall; Arthur E Frankel
Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys.
Leukemia & lymphoma 2004;45(8):1647-56.
2004: Tie Fu Liu; Jeffrey O Urieto; Joseph E Moore; Mark Steven Miller; A Corinne Lowe; Andrew Thorburn; Arthur E Frankel
Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity.
Experimental hematology 2004;32(3):277-81.
2004: Andrew Thorburn; Jacqueline Thorburn; Arthur E Frankel
Induction of apoptosis by tumor cell-targeted toxins.
Apoptosis : an international journal on programmed cell death 2004;9(1):19-25.
2004: Arthur E Frankel
Reducing the immune response to immunotoxin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):13-5.
2004: Jeffrey O Urieto; TieFu Liu; Jennifer H Black; Kimberley A Cohen; Philip D Hall; Mark C Willingham; Lewis K Pennell; Donna E Hogge; Robert J Kreitman; Arthur E Frankel
Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.
Protein expression and purification 2004;33(1):123-33.
2003: Tie Fu Liu; Mark C Willingham; Stephen B Tatter; Kimberley A Cohen; A Corinne Lowe; Andrew Thorburn; Arthur E Frankel
Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells.
Bioconjugate chemistry 2003;14(6):1107-14.
2003: Tie Fu Liu; Kimberley A Cohen; Mark C Willingham; Stephen B Tatter; Raj K Puri; Arthur E Frankel
Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture.
Journal of neuro-oncology 2003;65(1):77-85.
2003: Girish Mishra; Tie Fu Liu; Arthur E Frankel
Recombinant toxin DAB389EGF is cytotoxic to human pancreatic cancer cells.
Expert opinion on biological therapy 2003;3(7):1173-80.
2003: Arthur E Frankel; Donald R Fleming; Philip D Hall; Bayard L Powell; Jennifer H Black; Carole Leftwich; Ronald B Gartenhaus
A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3555-61.
2003: Arthur E Frankel; David M Neville; Thomas A Bugge; Robert J Kreitman; Stephen H Leppla
Immunotoxin therapy of hematologic malignancies.
Seminars in oncology 2003;30(4):545-57.
2003: Tie Fu Liu; Stephen B Tatter; Mark C Willingham; Mitchell Yang; Jennifer Hu; Arthur E Frankel
Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy.
Molecular cancer therapeutics 2003;2(8):783-7.
2003: Tie Fu Liu; Kimberley A Cohen; Jason G Ramage; Mark C Willingham; Andrew Thorburn; Arthur E Frankel
A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells.
Cancer research 2003;63(8):1834-7.
2003: Arthur E Frankel; Donald R Fleming; Bayard L Powell; Ronald B Gartenhaus
DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia.
Expert opinion on biological therapy 2003;3(1):179-86.
2003: Jacqueline Thorburn; Arthur E Frankel; Andrew Thorburn
Apoptosis by leukemia cell-targeted diphtheria toxin occurs via receptor-independent activation of Fas-associated death domain protein.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):861-5.
2003: Kimberley A Cohen; TieFu Liu; Reid Bissonette; Raj K Puri; Arthur E Frankel
DAB389EGF fusion protein therapy of refractory glioblastoma multiforme.
Current pharmaceutical biotechnology 2003;4(1):39-49.
2003: Arthur E Frankel; Han-Mo Koo; Stephen H Leppla; Nicholas S Duesbery; George Vande Woude
Novel protein targeted therapy of metastatic melanoma.
Current pharmaceutical design 2003;9(25):2060-6.
2003: Jennifer H Black; JA McCubrey; Mark C Willingham; Jason G Ramage; Donna E Hogge; Arthur E Frankel
Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
Leukemia 2003;17(1):155-9.
2003: Jason G Ramage; Daniel A Vallera; Jennifer H Black; Peter D Aplan; Ursula R Kees; Arthur E Frankel
The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells.
Leukemia research 2003;27(1):79-84.
2002: Arthur E Frankel; Miloslav Beran; Donna E Hogge; Bayard L Powell; Andrew Thorburn; Yong Q Chen; Daniel A Vallera
Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.
Experimental hematology 2002;30(11):1316-23.
2002: Philip D Hall; Bassem I Razzouk; Tony E Willoughby; Thomas Williams McLean; Arthur E Frankel
The majority of children and adolescents with acute myeloid leukemia have detectable anti-DT388-GMCSF IgG concentrations, but at concentrations that should not preclude in vivo activity.
Journal of pediatric hematology/oncology 2002;24(7):521-6.
2002: Arthur E Frankel; Bayard L Powell; Nicholas S Duesbery; George Vande Woude; Stephen H Leppla
Anthrax fusion protein therapy of cancer.
Current protein & peptide science 2002;3(4):399-407.
2002: Arthur E Frankel
New HER2-directed therapies for breast cancer. Commentary re: C. I. Spiridon et al., Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity. Clin. Cancer Res., 8: 1720-1730, 2002.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(6):1699-701.
2002: Arthur E Frankel; Bayard L Powell; Philip D Hall; L Douglas Case; Robert J Kreitman
Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):1004-13.
2002: Michaela Feuring-Buske; Arthur E Frankel; Richard L Alexander; Brigitte Gerhard; Donna E Hogge
A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Cancer research 2002;62(6):1730-6.
2002: Arthur E Frankel; Patrick Rossi; Timothy M Kuzel; Francine Foss
Diphtheria fusion protein therapy of chemoresistant malignancies.
Current cancer drug targets 2002;2(1):19-36.
2002: Patrick B Thomas; Stephen J Delatte; Aimee Sutphin; Arthur E Frankel; Edward P Tagge
Effective targeted cytotoxicity of neuroblastoma cells.
Journal of pediatric surgery 2002;37(3):539-44.
2002: Arthur E Frankel; Thomas H Bugge; Shihui Liu; Daniel A Vallera; Stephen H Leppla
Peptide toxins directed at the matrix dissolution systems of cancer cells.
Protein and peptide letters 2002;9(1):1-14.
2002: Arthur E Frankel; Bayard L Powell; Michael B Lilly
Diphtheria toxin conjugate therapy of cancer.
Cancer chemotherapy and biological response modifiers 2002;20():301-13.
2001: Richard L Alexander; Jason G Ramage; Gregory Kucera; M A Caligiuri; Arthur E Frankel
High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein.
Leukemia research 2001;25(10):875-81.
2001: Arthur E Frankel; Bayard L Powell; Daniel A Vallera; D M Neville
Chimeric fusion proteins--diphtheria toxin-based.
Current opinion in investigational drugs (London, England : 2000) 2001;2(9):1294-301.
2001: Arthur E Frankel; Maria R Baer; D E Hogge; Robert Stuart
Immunotherapy of acute myeloid leukemia.
Current pharmaceutical biotechnology 2001;2(3):209-15.
2001: Philip D Hall; Gabriel Virella; T Willoughby; Daniel Atchley; Robert J Kreitman; Arthur E Frankel
Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia.
Clinical immunology (Orlando, Fla.) 2001;100(2):191-7.
2001: M Kiser; JA McCubrey; Linda Steelman; John G Shelton; Jason G Ramage; Richard L Alexander; Gregory Kucera; M Pettenati; Mark C Willingham; Mark Steven Miller; Arthur E Frankel
Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice.
Leukemia 2001;15(5):814-8.
2000: Arthur E Frankel; E L Sievers; David A Scheinberg
Cell surface receptor-targeted therapy of acute myeloid leukemia: a review.
Cancer biotherapy & radiopharmaceuticals 2000;15(5):459-76.
2000: Arthur E Frankel; Jason G Ramage; M Kiser; R Alexander; Gregory Kucera; Mark Steven Miller
Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor.
Protein engineering 2000;13(8):575-81.
2000: Richard L Alexander; Gregory Kucera; B Klein; Arthur E Frankel
In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein.
Bioconjugate chemistry 2000;11(4):564-8.
2000: Arthur E Frankel; JA McCubrey; Mark Steven Miller; Stephen J Delatte; Jason G Ramage; M Kiser; Gregory Kucera; Richard L Alexander; M Beran; Edward P Tagge; Robert J Kreitman; Donna E Hogge
Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias.
Leukemia 2000;14(4):576-85.
2000: Arthur E Frankel; Robert J Kreitman; Edward A Sausville
Targeted toxins.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):326-34.
1999: CE Hotchkiss; Philip D Hall; J Mark Cline; Mark C Willingham; Robert J Kreitman; J Gardin; A Latimer; Jason G Ramage; Theodore Feely; Stephen J Delatte; Edward P Tagge; Arthur E Frankel
Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys.
Toxicology and applied pharmacology 1999;158(2):152-60.
1999: CN Kim; Kapil N Bhalla; R J Kreitman; M C Willingham; Philip D Hall; Edward P Tagge; T Jia; Arthur E Frankel
Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells.
Leukemia research 1999;23(6):527-38.
1999: Arthur E Frankel; Jason G Ramage; A Latimer; Theodore Feely; Stephen J Delatte; Philip D Hall; Edward P Tagge; Robert J Kreitman; Mark C Willingham
High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials.
Protein expression and purification 1999;16(1):190-201.
1999: Philip D Hall; Mark C Willingham; Robert J Kreitman; Arthur E Frankel
DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia.
Leukemia 1999;13(4):629-33.
1998: Arthur E Frankel; M Lilly; Robert J Kreitman; Donna E Hogge; M Beran; M H Freedman; P D Emanuel; C McLain; Philip D Hall; Edward P Tagge; M Berger; Connie Eaves
Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.
Blood 1998;92(11):4279-86.
1998: Donna E Hogge; C L Willman; Robert J Kreitman; M Berger; Philip D Hall; K J Kopecky; C McLain; Edward P Tagge; Connie J Eaves; Arthur E Frankel
Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein.
Blood 1998;92(2):589-95.
1998: Arthur E Frankel; Philip D Hall; C McLain; Ahmad R Safa; Edward P Tagge; Robert J Kreitman
Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF.
Bioconjugate chemistry 1998;9(4):490-6.
1998: Philip D Hall; Robert J Kreitman; Mark C Willingham; Arthur E Frankel
Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice.
Toxicology and applied pharmacology 1998;150(1):91-7.
1997: Arthur E Frankel; Philip D Hall; C Burbage; Jana Vesely; Mark C Willingham; Kapil N Bhalla; Robert J Kreitman
Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein.
Blood 1997;90(9):3654-61.
1997: Arthur E Frankel; Joseph H Laver; Mark C Willingham; Linda J Burns; John H Kersey; Daniel A Vallera
Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin.
Leukemia & lymphoma 1997;26(3-4):287-98.
1997: C Burbage; Edward P Tagge; B Harris; Philip D Hall; T Fu; Mark C Willingham; Arthur E Frankel
Ricin fusion toxin targeted to the human granulocyte-macrophage colony stimulating factor receptor is selectively toxic to acute myeloid leukemia cells.
Leukemia research 1997;21(7):681-90.
1997: Arthur E Frankel; T Fu; C Burbage; Edward P Tagge; B Harris; Jana Vesely; Mark C Willingham
Lectin-deficient ricin toxin intoxicates cells bearing the D-mannose receptor.
Carbohydrate research 1997;300(3):251-8.
1997: Arthur E Frankel; T Fu; C Burbage; John C. Chandler; Mark C Willingham; Edward P Tagge
IL2 fused to lectin-deficient ricin is toxic to human leukemia cells expressing the IL2 receptor.
Leukemia 1997;11(1):22-30.
1996: T Fu; C Burbage; Edward P Tagge; Thomas E Brothers; Mark C Willingham; Arthur E Frankel
Ricin toxin contains three lectin sites which contribute to its in vivo toxicity.
International journal of immunopharmacology 1996;18(12):685-92.
1996: Arthur E Frankel; C Burbage; T Fu; Edward P Tagge; John C. Chandler; Mark C Willingham
Ricin toxin contains at least three galactose-binding sites located in B chain subdomains 1 alpha, 1 beta, and 2 gamma.
Biochemistry 1996;35(47):14749-56.
1996: D A Vallera; Linda J Burns; Arthur E Frankel; A R Sicheneder; R Gunther; K Gajl-Peczalska; C A Pennell; J H Kersey
Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies.
Journal of immunological methods 1996;197(1-2):69-83.
1996: Arthur E Frankel; C Burbage; T Fu; Edward P Tagge; John C. Chandler; Mark C Willingham
Characterization of a ricin fusion toxin targeted to the interleukin-2 receptor.
Protein engineering 1996;9(10):913-9.
1996: John C. Chandler; Arthur E Frankel; Edward P Tagge
Genetic engineering of immunotoxins.
Seminars in pediatric surgery 1996;5(3):206-11.
1996: Edward P Tagge; DU Tagge; John C. Chandler; B R Pitre; G Haddad; Arthur E Frankel; M C Willingham; A Julian Garvin; T S Papas
Molecular biology and the pediatric surgeon: definitions and basic methodology.
Seminars in pediatric surgery 1996;5(3):139-48.
1996: Edward P Tagge; John C. Chandler; B Harris; M Czako; Laszlo Marton; Mark C Willingham; C Burbage; Lawrence B Afrin; Arthur E Frankel
Preproricin expressed in Nicotiana tabacum cells in vitro is fully processed and biologically active.
Protein expression and purification 1996;8(1):109-18.
1996: Gian G Re; C Waters; L Poisson; Mark C Willingham; K Sugamura; Arthur E Frankel
Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells.
Cancer research 1996;56(11):2590-5.
1996: Arthur E Frankel; D FitzGerald; C Siegall; O W Press
Advances in immunotoxin biology and therapy: a summary of the Fourth International Symposium on Immunotoxins.
Cancer research 1996;56(4):926-32.
1995: Arthur E Frankel; Edward P Tagge; Mark C Willingham
Clinical trials of targeted toxins.
Seminars in cancer biology 1995;6(5):307-17.
1994: Lawrence B Afrin; H Gulick; Jana Vesely; Mark C Willingham; Arthur E Frankel
Expression of oligohistidine-tagged ricin B chain in Spodoptera frugiperda.
Bioconjugate chemistry 1994;5(6):539-46.